In a press release last May, Eli Lilly announced positive results from a phase 3 trial of donanemab antibody therapy to treat early-stage Alzheimer's disease. Now, the study, which included 1,736 people in eight countries over an 18-month period, is published in the journal JAMA and shows that, in some cases, clinical progression of the disease was slowed.
The drug lecanemab (Leqembi™) has received full approval as a treatment for early Alzheimer's disease by the US Food and Drug Administration (FDA), after confirming its clinical benefit in a trial involving 1,795 patients. The FDA highlights the warning that in rare cases it can cause serious and potentially life-threatening side effects.
The use of hormonal replacement therapy (HRT) for menopause is associated with the development of dementia and Alzheimer's disease, even for short prescriptions before the age of 55, according to an analysis of data from the Danish national registry published in The BMJ. The research - which observes associations and cannot determine causality - also shows that the use of progesterone alone and vaginal oestrogen are not associated with the development of dementia.
An international team of scientists, led by Stanford University (United States), has designed a study to analyse the relationship between herpes zoster virus infections and the development of dementia. To do so, they took advantage of the introduction of the Zostavax vaccine against this virus in 2013 in Wales (UK), which people over the age of 80 could not receive. After reviewing data from people around this age over the following seven years, they concluded that the vaccine reduced the relative risk of dementia by 20%. According to the authors, their study, which is in prepublication form and has not been peer-reviewed, "leads to the conclusion that shingles vaccination is most likely an effective way to prevent or delay the onset of dementia".
Research led by scientists at Harvard Medical School (USA) has isolated small aggregates of amyloid from the brains of post-mortem Alzheimer's patients. The achievement has made it possible to study the structure of these "clumps", which exist outside plaques and are considered highly toxic, and to test their effect on synapses. In addition, the authors have shown that the drug lecanemab, recently approved by the FDA, is able to bind to them and help neutralise their action. The results are published in the journal Neuron.
A press release from Eli Lilly claims that its antibody treatment, donanemab, significantly slowed cognitive and functional decline in a phase 3 study of early-stage Alzheimer's disease. The results have not yet been published in a scientific journal.
Swedish research involving more than 6,000 male footballers in the country's top division (between 1924 and 2019) indicates that they were 1.5 times more likely to develop a neurodegenerative disease compared to the population analysed who were not involved in professional football. Unlike outfield players, goalkeepers did not have this increased risk, which, according to the authors, supports the hypothesis that impacts to the head when striking the ball could explain the increased risk. The study is published in The Lancet Public Health.
Artificial intelligence algorithms using ChatGPT - the OpenAI company's GPT-3 language model - can identify speech features to predict the early stages of Alzheimer's disease with 80 per cent accuracy. The neurodegenerative disease causes a loss of the ability to express oneself that the algorithms could recognise, according to the journal PLOS Digital Health.
A study published in the journal Neurology claims to have confirmed the usefulness of a biomarker in blood to diagnose Alzheimer's disease without the need for other tests.
A few weeks ago, a press release from the Biogen and Eisai companies reported significant results from their lecanemab antibody for the treatment of early-stage Alzheimer's. The data from the phase 3 trial are now published in the New England Journal of Medicine, coinciding with the CTAD conference on Alzheimer's disease clinical trials in San Francisco. Data from the phase 3 clinical trial are now published in the New England Journal of Medicine, coinciding with the 15th CTAD Alzheimer's disease clinical trials conference in San Francisco.